Photodynamic therapy (PDT), which uses targeted photosensitizing drugs, has been regarded as a promising method for cancer therapy. In the present study, photosensitizer red phosphorus modified P25 nanophotosensitizers (P25-RP) were generated, which were coated with platelet membrane (P25-RP@PLT) extracted from platelet rich plasma. The biocompatibility of P25-RP was demonstrated by cell counting kit-8 (CCK-8) and optical microscope assay, more than 93 % cells in the concentration of 100 μg/ml of P25-RP suspension after co-incubation for 24 h were still kept alive. The antitumor performance of P25-RP@PLT was evaluated via CCK-8 assay, flow cytometry and fluorescence staining of live/dead cells. The experiment results showed that P25-RP@PLT could ablate 55 % malignant tumor cells upon laser irradiation within 5 min, which was 10 % higher than P25-RP alone against cancer cells. Mechanistically, the cancer cell toxicity of P25-RP@PLT nanophotosensitizers was attributed to its heterojunction structure that broadens the absorption spectra, whereas PLT membrane coating technology allows for immune escape and selective adhesion capacity to cancer cells. This work provided a novel pathway on the design of novel visible-light-driven photosensitizer for cancer therapy.
Keywords: immune escape; photodynamic therapy; platelet membrane; red phosphorus modified P25; targeted therapy.
© 2022 Wiley-VHCA AG, Zurich, Switzerland.